Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 26;12(30):6358-6360.
doi: 10.12998/wjcc.v12.i30.6358.

Enhancing ulcerative colitis treatment with traditional Chinese medicine

Affiliations
Editorial

Enhancing ulcerative colitis treatment with traditional Chinese medicine

Wen-Rui Hao et al. World J Clin Cases. .

Abstract

Inflammatory bowel disease, particularly ulcerative colitis (UC), poses significant treatment challenges due to its chronic nature and potential for severe complications. This editorial reviews a recent network meta-analysis that evaluated the efficacy of and highlighted the superior outcomes achieved by combining each of five traditional Chinese medicine (TCM) formulations with mesalazine for the adjuvant treatment of UC. Clinical outcomes included enhanced mucosal healing, improved quality of life, and reduced recurrence rates. Additionally, the combination therapy resulted in a lower incidence of adverse reactions compared with mesalazine monotherapy. Despite these promising results, limitations such as variability in study quality and TCM dosage highlight the need for further high-quality, large-sample, multicenter randomized controlled trials. This editorial underscores the potential of TCM in enhancing UC management and calls for more rigorous research to substantiate these findings and refine clinical guidelines.

Keywords: Adjuvant therapy; Adverse reaction; Clinical efficacy; Network meta-analysis; Quality of life; Recurrence rate; Traditional Chinese medicine, Mesalazine; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All authors declare having no conflicts of interest.

References

    1. D'Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S. Management and treatment optimization of patients with mild to moderate ulcerative colitis. Expert Rev Clin Immunol. 2024;20:277–290. - PubMed
    1. Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023;330:951–965. - PubMed
    1. Guo M, Du X, Wang X. Inhibition of ferroptosis: A new direction in the treatment of ulcerative colitis by traditional Chinese medicine. J Ethnopharmacol. 2024;324:117787. - PubMed
    1. Zhao ZH, Dong YH, Jiang XQ, Wang J, Qin WL, Liu ZY, Zhang XQ, Wei YJ. Five commonly used traditional Chinese medicine formulas in the treatment of ulcerative colitis: A network meta-analysis. World J Clin Cases. 2024;12:5067–5082. - PMC - PubMed
    1. Zhang S, Zhao L, Shen H, Tang Z, Qin D, Li J, Zhang B, Yang G, Chen M, Wu K, Liu Z, Yang H, Wang H, Zong Y, Chen Y, Xiao S, Cai Q. International clinical practice guideline on the use of traditional Chinese medicine for ulcerative colitis by Board of Specialty Committee of Digestive System Disease of World Federation of Chinese Medicine Societies (2023) Phytother Res. 2024;38:970–999. - PubMed

Publication types

LinkOut - more resources